Hosted on MSN29d
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
Eligible patients had unresectable locally advanced or limited metastatic disease (single-site metastases). They had at least one measurable lesion, an Eastern Cooperative Oncology Group ...
Targeted Oncology4d
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
Cure Today7d
Padcev Significantly Improves OS in Real-World Urothelial Carcinoma
Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall ...
Monthly Prescribing Reference3d
Zongertinib Under Review for HER2-Mutant Advanced NSCLC
The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Oncology Nurse Advisor12d
FDA Approves Datroway for Advanced HR+, HER2- Breast Cancer
Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.
Targeted Oncology3d
FDA Grants Priority Review to Zongertinib in HER2-Mutant NSCLC
Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...
MedPage Today1mon
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ...